Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Novartis’ secukinumab bests Enbrel in psoriasis study
August 2013
SHARING OPTIONS:

ZURICH—In a late-stage study, secukinumab was shown to be superior to Amgen's Enbrel, Novartis announced in early July. In a head-to-head Phase III trial of 1,307 patients, secukinumab proved to be more effective than Enbrel in clearing skin in patients with moderate to severe plaque-type psoriasis. The FIXTURE trial was a randomized, double-blind, placebo-controlled, multicenter global study of subcutaneous secukinumab, and the compound's safety profile was consistent with Phase II study results, with no new safety concerns identified. Full study results should be presented later this year, and Novartis notes that it plans to file for regulatory approval for the drug by the end of 2013. Secukinumab selectively targets IL-17A, a central cytokine in the development of psoriasis that is found in high concentration in affected skin areas.    

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.